Read by QxMD icon Read


Elsebeth Lynge, Berit Andersen, Jette Christensen, Dorthe Ejersbo, Kirsten Jochumsen, Tonje Johansen, Jette Kolding Kristensen, Lise Grupe Larsen, Frank Mehnert, Ellen Mikkelsen, Karsten Nielsen, Carsten Rygaard, Reza Serizawa, Marianne Waldstrøm
INTRODUCTION: Despite an intensive screening activity, the incidence of cervical cancer in Denmark has remained stable for the last 15 years, while regional differences have increased. To search for explanations, we investigated possible weaknesses in the screening program. MATERIAL AND METHODS: Data on the screen-targeted women were retrieved from Statistics Denmark. Data on screening activity were retrieved from the annual reports from 2009 to 2015 on quality of cervical screening...
March 2018: Acta Oncologica
Mette Hjortkjær, Marianne Waldstrøm, Anders Jakobsen, Hanne Kanstrup, Erik Søgaard-Andersen, Karina Dahl Steffensen
BRCA1/2 mutation status in epithelial ovarian cancer (EOC) presently relies on genetic testing which is resource consuming. Immunohistochemistry is cheap, fairly reproducible, and may identify gene product alterations due to both germline and somatic mutations and other defects along the BRCA gene pathway (BRCAness phenomenon), which is important when treatment with poly (adenosine-diphosphate-ribose) polymerase (PARP) inhibitors is considered. The aim of this study was to investigate immunohistochemical detection of BRCA1 and PARP expression in EOC and their possible prognostic relevance...
March 2017: International Journal of Gynecological Pathology
Karina Dahl Steffensen, Marianne Waldstrøm, Ivan Brandslund, Bente Lund, Sarah Mejer Sørensen, Max Petzold, Anders Jakobsen
The majority of ovarian cancer patients with advanced disease at diagnosis will relapse following primary treatment, with a dismal prognosis. Monitoring the levels of serum markers in patients under follow-up may be essential for the early detection of relapse, and for distinguishing high-risk patients from those with less aggressive disease. The aim of the present study was to investigate the possible predictive value of human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) in relation to recurrence of epithelial ovarian cancer by measuring the two markers during follow-up subsequent to surgery and adjuvant first-line carboplatin/paclitaxel chemotherapy...
June 2016: Oncology Letters
Louise T Thomsen, Christian Dehlendorff, Jette Junge, Marianne Waldstrøm, Doris Schledermann, Kirsten Frederiksen, Susanne K Kjaer
In this prospective cohort study, we compared the performance of human papillomavirus (HPV) mRNA and DNA testing of women with atypical squamous cells of undetermined significance (ASC-US) during cervical cancer screening. Using a nationwide Danish pathology register, we identified women aged 30-65 years with ASC-US during 2005-2011 who were tested for HPV16/18/31/33/45 mRNA using PreTect HPV-Proofer (n = 3,226) or for high-risk HPV (hrHPV) DNA using Hybrid Capture 2 (HC2) (n = 9,405) or Linear Array HPV-Genotyping test (LA) (n = 1,533)...
October 15, 2016: International Journal of Cancer. Journal International du Cancer
Annabeth Høgh Petersen, Mads Malik Aagaard, Henriette Roed Nielsen, Karina Dahl Steffensen, Marianne Waldstrøm, Anders Bojesen
Accurate estimation of cancer risk in HBOC families often requires BRCA1/2 testing, but this may be impossible in deceased family members. Previous, testing archival formalin-fixed, paraffin-embedded (FFPE) tissue for germline BRCA1/2 variants was unsuccessful, except for the Jewish founder mutations. A high-throughput method to systematically test for variants in all coding regions of BRCA1/2 in archival FFPE samples of non-tumor tissue is described, using HaloPlex target enrichment and next-generation sequencing...
August 2016: European Journal of Human Genetics: EJHG
Karina Dahl Steffensen, Christine Vestergaard Madsen, Rikke Fredslund Andersen, Marianne Waldstrøm, Parvin Adimi, Anders Jakobsen
AIM: Treatment of multiresistant epithelial ovarian cancer (EOC) is palliative and patients who have become resistant after multiple lines of chemotherapy often have an unmet need for further and less toxic treatment. Anti-angiogenic therapy has attracted considerable attention in the treatment of EOC in combination with chemotherapy. However, only a minor subgroup will benefit from the treatment and there is an obvious need for new markers to select such patients. The purpose of this study was to investigate the effect of single-agent bevacizumab in multiresistant EOC and the importance of circulating cell-free DNA (cfDNA) in predicting treatment response...
October 2014: European Journal of Cancer
Raluca Ioana Panculescu-Gatej, Anca Sirbu, Sorin Dinu, Maria Waldstrom, Paul Heyman, Dimitru Murariu, Angela Petrescu, Camelia Szmal, Gabriela Oprisan, Ake Lundkvist, Cornelia S Ceianu
Hemorrhagic fever with renal syndrome (HFRS) has been confirmed by serological methods during recent years in Romania. In the present study, focus-reduction neutralization tests (FRNT) confirmed Dobrava hantavirus (DOBV) as the causative agent in some HFRS cases, but could not distinguish between DOBV and Saaremaa virus (SAAV) infections in other cases. DOBV was detected by a DOBV-specific TaqMan assay in sera of nine patients out of 22 tested. Partial sequences of the M genomic segment of DOBV were obtained from sera of three patients and revealed the circulation of two DOBV lineages in Romania...
May 2014: Vector Borne and Zoonotic Diseases
Karina Dahl Steffensen, Marta Smoter, Marianne Waldstrøm, Bartłomiej Grala, Lubomir Bodnar, Rafał Stec, Cezary Szczylik, Anders Jakobsen
In oncology, a rational approach to identify patients who are likely to benefit from therapy, already before initiation of treatment, is urgently required. Excision repair cross-complementation group 1 enzyme (ERCC1) has been proposed as a molecular predictor of clinical resistance to platinum-based chemotherapy. Other data suggest Tau protein expression as a predictor of clinical outcome in cancer patients treated with paclitaxel-based chemotherapy as low tau expression may render microtubules more vulnerable to paclitaxel...
May 2014: International Journal of Oncology
Kirsten Quyen Nguyen Knudsen, Pia Engell Winter, Annemette Wildfang Lykkebo, Marianne Waldstrøm
Perivascular epithelioid cell tumours (PEComas) are rare tumours with unknown malignant potential. We report a case of a 48-year-old woman, who had had many tumours, initially diagnosed as leiomyomas, removed from her uterus and vagina over 16 years. A recurrent tumour and revision of prior specimens revealed PEComa. As free surgical margins could not be obtained, the woman is regularly controlled by magnetic resonance imaging. So far recurrence has not been detected. This case shows that knowledge of PEComas is important to ensure relevant follow-up as these are low malignant tumours that tend to reoccur...
April 22, 2013: Ugeskrift for Laeger
Karina Dahl Steffensen, Marianne Waldstrøm, Niels Pallisgård, Bente Lund, Kjell Bergfeldt, Jessica Wihl, Nina Keldsen, Christian Marth, Ignace Vergote, Anders Jakobsen
OBJECTIVE: The increasing number of negative trials for ovarian cancer treatment has prompted an evaluation of new biologic agents, which in combination with chemotherapy may improve survival. The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab. PATIENTS AND METHODS: Major eligibility criteria were relapsed ovarian/fallopian/peritoneal cancer patients with platinum-resistant disease, measurable disease by GCIG CA125 criteria and KRAS wild-type...
January 2013: International Journal of Gynecological Cancer
Karina Dahl Steffensen, Marianne Waldstrøm, Ivan Brandslund, Max Petzold, Anders Jakobsen
OBJECTIVE: A risk-of-ovarian-malignancy algorithm (ROMA) based on human epididymis protein 4 (HE4) and CA-125 has been reported to categorize women with a pelvic mass into high or low risk of ovarian malignancy. Originally, the ROMA score was developed for diagnostic purposes and the clinical application of HE4 for other purposes such as a predictor of survival or platinum resistance has not been extensively investigated. The objective of the present study was to evaluate the prognostic importance of prechemotherapy combined levels of HE4 and CA-125 and prediction of platinum resistance...
November 2012: International Journal of Gynecological Cancer
Christine Vestergaard Madsen, Karina Dahl Steffensen, Marianne Waldstrøm, Anders Jakobsen
Introduction. The well-documented role of the PDGF system in tumor growth and angiogenesis has prompted the development of new biological agents targeting the PDGF system. The aim of the present study was to analyze the expression of the PDGF-receptors in ovarian cancer and to investigate its relation to histopathological parameters and long-term overall survival. Methods. The immunohistochemical expression of PDGFR-α and PDGFR-β was investigated in tumor and stromal cells in 170 patients with histologically verified epithelial ovarian cancer...
2012: Pathology Research International
Christine Vestergaard Madsen, Karina Dahl Steffensen, Dorte Aalund Olsen, Marianne Waldstrøm, Charlotte Hasselholt Søgaard, Ivan Brandslund, Anders Jakobsen
BACKGROUND: New biological markers with predictive or prognostic value are highly warranted in the treatment of ovarian cancer. The platelet-derived growth factor (PDGF) system and fibroblast growth factor (FGF) system are important components in tumor growth and angiogenesis. MATERIALS AND METHODS: Pre-surgery peripheral blood samples were collected consecutively from 213 patients (42 with normal ovaries, 54 with benign, 21 with borderline, and 96 with malignant ovarian tumors) undergoing surgery for an untreated pelvic mass...
September 2012: Anticancer Research
Christine Vestergaard Madsen, Karina Dahl Steffensen, Dorte Aalund Olsen, Marianne Waldstrøm, Maja Smerdel, Parvin Adimi, Ivan Brandslund, Anders Jakobsen
UNLABELLED: HASH(0x30f8d68) INTRODUCTION: Anti-VEGF treatment has proven effective in recurrent ovarian cancer. However, the identification of the patients most likely to respond is still pending. It is well known that the angiogenesis is regulated by several other pro-angiogenic proteins, e.g. the platelet - derived growth factor (PDGF) system and the fibroblast growth factor (FGF) system. These other signaling pathways may remain active or become upregulated during anti-VEGF treatment...
2012: Journal of Ovarian Research
Marianne Waldstrøm, Rikke Kølby Christensen, Dorthe Ørnskov
BACKGROUND: The objective of the current study was to investigate the clinical performance of detecting high-grade lesions with the CINtec PLUS p16(INK4a)/Ki-67 dual stain and the APTIMA human papillomavirus (HPV) Assay in a cohort of women with low-grade squamous intraepithelial lesion (LSIL) cytology. The authors also assessed the reproducibility of the evaluation of immunocytochemical staining. METHODS: The 2 tests were performed on liquid-based residual material from 469 women with LSILs...
March 2013: Cancer Cytopathology
M Waldstrom, D Ornskov
OBJECTIVE: The effect of triaging women with atypical squamous cells of undetermined significance (ASC-US) with human papillomavirus (HPV) DNA testing has been well documented. New tests detecting HPV E6/E7 mRNA are emerging, claiming to be more specific for detecting high-grade disease. We evaluated the clinical performance of two HPV tests: the Linear Array HPV genotyping test (LA) detecting HPV DNA from 37 oncogenic and non-oncogenic HPV types and the Aptima HPV assay detecting E6/E7 mRNA from 14 oncogenic HPV types...
December 2012: Cytopathology: Official Journal of the British Society for Clinical Cytology
Karina Dahl Steffensen, Marianne Waldstrøm, Anni Grove, Bente Lund, Niels Pallisgård, Anders Jakobsen
OBJECTIVE: An increasing body of evidence has suggested that epithelial ovarian cancer (EOC) patients can broadly be divided into 2 groups on the basis of histopathologic parameters and molecular profiles. Type 1 tumors are slow-growing tumors with inherent mutations such as KRAS or BRAF mutations, whereas type 2 tumors are more rapidly growing tumors of which many contain TP53 mutations. In the present study, we performed a comprehensive study in a large Danish material to evaluate the clinical importance...
December 2011: International Journal of Gynecological Cancer
Karina Dahl Steffensen, Ayesha B Alvero, Yang Yang, Marianne Waldstrøm, Pei Hui, Jennie C Holmberg, Dan-Arin Silasi, Anders Jakobsen, Thomas Rutherford, Gil Mor
Epithelial ovarian cancer stem cells (EOC stem cells) have been associated with recurrence and chemoresistance. CD44 and CK18 are highly expressed in cancer stem cells and function as tools for their identification and characterization. We investigated the association between the number of CD44+ EOC stem cells in ovarian cancer tumors and progression-free survival. EOC stem cells exist as clusters located close to the stroma forming the cancer stem cell "niche". 17.1% of the samples reveled high number of CD44+ EOC stem cells (>20% positive cells)...
2011: Journal of Oncology
Marianne Waldstrøm, Dorthe Ornskov
CONTEXT: Human papillomavirus (HPV) testing is widely used in the triage of women with a borderline smear result but the efficiency of testing women with low-grade squamous intraepithelial lesion (LSIL) is less clear, mainly because of lack of specificity. New HPV tests are emerging, which detect E6/E7messenger RNA (mRNA), and preliminary data suggest that they might have a higher specificity. However, mRNA is less stable than DNA, thus posing a challenge to the preservation abilities of the cell-collecting medium...
August 2011: Archives of Pathology & Laboratory Medicine
Karina Dahl Steffensen, Marianne Waldstrøm, Ivan Brandslund, Anders Jakobsen
OBJECTIVE: Human epididymis protein 4 (HE4) has attracted a lot of interest as a relatively novel biomarker for ovarian carcinoma. Research focus has been directed at HE4 as a diagnostic tool with potential for better triage of women with adnexal masses but the prognostic aspect of HE4 in ovarian cancer patients remains to be elucidated. The aim of the present study was to investigate the prognostic value of prechemotherapy serum HER2, cancer antigen 125 (CA125), and HE4 levels in ovarian cancer patients receiving standard combination chemotherapy...
August 2011: International Journal of Gynecological Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"